Physician profile
Daniel L Watson
NPI 1689618225
$8,101.05
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,793 · 2020: $3,208 · 2021: $1,740 · 2022: $1,331 · 2024: $28.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,109.76 | 2019-2022 | |
| Astellas Pharma US INC | $1,027.72 | 2019-2022 | |
| Healthtronics Stone Solutions, LLC | $850.41 | 2019-2021 | |
| Janssen Biotech, INC. | $687.62 | 2019-2022 | |
| Boston Scientific Corporation | $379.98 | 2019-2022 | |
| Abbvie INC. | $372.74 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $331.03 | 2019-2024 | Provenge |
| Pfizer INC. | $292.95 | 2019-2022 | |
| Aytu Biopharma, INC. | $227.60 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $219.81 | 2019-2022 | |
| Blue Earth Diagnostics | $200.75 | 2019-2022 | |
| Neotract INC. | $167.81 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $142.91 | 2020-2022 | |
| Johnson & Johnson Health Care Systems INC. | $133.66 | 2021 | |
| Procept Biorobotics Corporation | $127.72 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $119.47 | 2022 | |
| Endo Pharmaceuticals INC. | $98.35 | 2019-2022 | |
| Amgen INC. | $96.61 | 2019-2020 | |
| Myovant Sciences INC. | $90.35 | 2021-2022 | |
| Smith+Nephew, INC. | $88.57 | 2020 | |
| Urogen Pharma, INC. | $68.92 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $62.99 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $47.79 | 2019-2021 | |
| Foundation Medicine, INC. | $23.33 | 2021 | |
| Convatec INC. | $22.46 | 2021 | |
| Clarus Therapeutics INC. | $21.34 | 2021 | |
| Coloplast Corp | $17.03 | 2019 | |
| Clovis Oncology, INC. | $16.27 | 2020 | |
| Urovant Sciences INC | $16.05 | 2022 | |
| Myriad Genetic Laboratories, INC. | $13.91 | 2021 | |
| Mission Pharmacal Company | $13.87 | 2019 | |
| Hollister Incorporated | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.